Upregulation of endogenous TRAIL-elicited apoptosis is essential for metformin-mediated antitumor activity against TNBC and NSCLC
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) shows promising antitumor activity in preclinical studies. However, the efficacy of recombinant TRAIL in clinical trials is compromised by its short serum half-life and low in vivo stability. Induction of endogenous TRAIL may overcome t...
Main Authors: | Shuang Liu, Erik V. Polsdofer, Lukun Zhou, Sanbao Ruan, Hui Lyu, Defu Hou, Hao Liu, Ann D. Thor, Zhimin He, Bolin Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-06-01
|
Series: | Molecular Therapy: Oncolytics |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2372770521000620 |
Similar Items
-
Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51
by: Jung Ok Lee, et al.
Published: (2019-10-01) -
Metformin-repressed miR-381-YAP-snail axis activity disrupts NSCLC growth and metastasis
by: Dan Jin, et al.
Published: (2020-01-01) -
Caloric restriction and metformin selectively improved LKB1-mutated NSCLC tumor response to chemo- and chemo-immunotherapy
by: Gloriana Ndembe, et al.
Published: (2024-01-01) -
Metformin suppresses NFE2L1 pathway activation to inhibit gap junction beta protein expression in NSCLC
by: Shuo Yu, et al.
Published: (2024-04-01) -
HER3 functions as an effective therapeutic target in triple negative breast cancer to potentiate the antitumor activity of gefitinib and paclitaxel
by: Hui Lyu, et al.
Published: (2023-09-01)